Evaluation of the effect of the administration of a glucosamine‑containing supplement on biomarkers for cartilage metabolism in soccer players: A randomized double‑blind placebo‑controlled study

Tsuruta,Akifumi; Horiike,Takumi; Yoshimura,Masafumi; Nagaoka,Isao

doi:10.3892/mmr.2018.9396

Evaluation of the effect of the administration of a glucosamine‑containing supplement on biomarkers for cartilage metabolism in soccer players: A randomized double‑blind placebo‑controlled study

Authors:
- Akifumi Tsuruta
- Takumi Horiike
- Masafumi Yoshimura
- Isao Nagaoka
View Affiliations

Affiliations: Department of Host Defense and Biochemical Research, Juntendo University Graduate School of Medicine, Tokyo 113‑8421, Japan, Juntendo University Graduate School of Health and Sports Science, Chiba 270‑1695, Japan
Published online on: August 17, 2018 https://doi.org/10.3892/mmr.2018.9396
Pages: 3941-3948

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A randomized double‑blind placebo‑controlled clinical study was conducted to evaluate the chondroprotective action of glucosamine on healthy subjects (soccer players) without joint disorders. Collegiate soccer players (n=43) without joint disorders were randomly assigned to receive a glucosamine (2 g/day)‑containing supplement (n=22, glucosamine group) or a placebo (n=21, placebo group) for 16 weeks, and cartilage metabolism was evaluated by analyzing markers for type II collagen degradation urine C‑terminal telopeptide‑II (CTX‑II) and serum collagen type II cleavage (C2C) and synthesis urine C-terminal type II procollagen peptide (CPII). In the initial analysis of all subjects, urine CTX‑II level substantially decreased in the glucosamine group, but not in the placebo group after the intervention for 16 weeks (P=0.05). Moreover, CTX‑II level in the glucosamine group was also significantly lower than that in the placebo group at week 16 during the intervention. In the second analysis, to make the effect of the test supplement more clear, 41 subjects with less variation of exercise loading were evaluated. The results revealed that urine CTX‑II level significantly decreased in the glucosamine group (n=21), but not in the placebo group (n=20) after the intervention (P<0.05). Moreover, CTX‑II levels in the glucosamine group significantly decreased compared with the placebo group after the intervention (P<0.05). Both in the initial and second analyses, serum C2C level significantly decreased in the glucosamine group, but not in the placebo group after the intervention (P<0.05). In contrast, urine CPII level was not significantly changed even after the intervention in both the placebo and glucosamine groups. Importantly, no test supplement‑related adverse events were observed. These observations suggest that oral administration of glucosamine (2 g/day for 16 weeks) exerts a chondroprotective action on healthy subjects (soccer players) without joint disorders. This effect was achieved by improving cartilage metabolism (suppressing type II collagen degradation but maintaining type II collagen synthesis), without causing apparent adverse effects.

View Figures

View References

1	Roos H, Dahlberg L, Hoerrner LA, Lark MW, Thonar EJ, Shinmei M, Lindqvist U and Lohmander LS: Markers of cartilage matrix metabolism in human joint fluid and serum: The effect of exercise. Osteoarthritis Cartilage. 3:7–14. 1995. View Article : Google Scholar : PubMed/NCBI
2	Qi C and Changlin H: Effects of moving training on histology and biomarkers levels of articular cartilage. J Surg Res. 135:352–363. 2006. View Article : Google Scholar : PubMed/NCBI
3	O'Kane JW, Hutchinson E, Atley LM and Eyre DR: Sport-related differences in biomarkers of bone resorption and cartilage degradation in endurance athletes. Osteoarthritis Cartilage. 14:71–76. 2006. View Article : Google Scholar : PubMed/NCBI
4	Buckwalter JA and Lane NE: Athletics and osteoarthritis. Am J Sports Med. 25:873–881. 1997. View Article : Google Scholar : PubMed/NCBI
5	Rousseau JC and Delmas PD: Biological markers in osteoarthritis. Nat Clin Pract Rheumatol. 3:346–356. 2007. View Article : Google Scholar : PubMed/NCBI
6	Poole AR: Biochemical/immunochemical biomarkers of osteoarthritis: Utility for prediction of incident or progressive osteoarthritis. Rheum Dis Clin North Am. 29:803–818. 2003. View Article : Google Scholar : PubMed/NCBI
7	Christgau S, Garnero P, Fledelius C, Moniz C, Ensig M, Gineyts E, Rosenquist C and Qvist P: Collagen type II C-telopeptide fragments as an index of cartilage degradation. Bone. 29:209–215. 2001. View Article : Google Scholar : PubMed/NCBI
8	Poole AR, Ionescu M, Fitzcharles MA and Billinghurst RC: The assessment of cartilage degradation in vivo: Development of an immunoassay for the measurement in body fluids of type II collagen cleaved by collagenases. J Immunol Methods. 294:145–153. 2004. View Article : Google Scholar : PubMed/NCBI
9	Shinmei M, Ito K, Matsuyama S, Yoshihara Y and Matsuzawa K: Joint fluid carboxy-terminal type II procollagen peptide as a marker of cartilage collagen biosynthesis. Osteoarthritis Cartilage. 1:121–128. 1993. View Article : Google Scholar : PubMed/NCBI
10	Schwenk TL and Costley CD: When food becomes a drug: Nonanabolic nutritional supplement use in athletes. Am J Sports Med. 30:907–916. 2002. View Article : Google Scholar : PubMed/NCBI
11	Gorsline RT and Kaeding CC: The use of NSAIDs and nutritional supplements in athletes with osteoarthritis: Prevalence, benefits, and consequences. Clin Sports Med. 24:71–82. 2005. View Article : Google Scholar : PubMed/NCBI
12	Ostojic SM, Arsic M, Prodanovic S, Vukovic J and Zlatanovic M: Glucosamine administration in athletes: Effects on recovery of acute knee injury. Res Sports Med. 15:113–124. 2007. View Article : Google Scholar : PubMed/NCBI
13	Nagaoka I: Joint health of athletes and the chondroprotective action of glucosamine. Juntendo Med J. 63:104–114. 2017. View Article : Google Scholar
14	McAlindon TE, LaValley MP, Gulin JP and Felson DT: Glucosamine and chondroitin for treatment of osteoarthritis: A systematic quality assessment and meta-analysis. JAMA. 283:1469–1475. 2000. View Article : Google Scholar : PubMed/NCBI
15	Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE and Gossett C: Long-term effects of glucosamine sulphate on osteoarthritis progression: A randomized, placebo-controlled clinical trial. Lancet. 357:251–256. 2001. View Article : Google Scholar : PubMed/NCBI
16	Pavelká K, Gatterová J, Olejarová M, Machacek S, Giacovelli G and Rovati LC: Glucosamine sulfate use and delay of progression of knee osteoarthritis: A 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 162:2113–2123. 2002. View Article : Google Scholar : PubMed/NCBI
17	Nagaoka I: Recent aspect of the chondroprotective and anti-inflammatory actions of glucosamine, a functional food. Juntendo Med J. 60:580–587. 2014. View Article : Google Scholar
18	Fenton JI, Chlebek-Brown KA, Peters TL, Caron JP and Orth MW: Glucosamine HCl reduces equine articular cartilage degradation in explant culture. Osteoarthritis Cartilage. 8:258–265. 2000. View Article : Google Scholar : PubMed/NCBI
19	Gouze JN, Bordji K, Gulberti S, Terlain B, Netter P, Magdalou J, Fournel-Gigleux S and Ouzzine M: Interleukin-1beta down-regulates the expression of glucuronosyltransferase I, a key enzyme priming glycosaminoglycan biosynthesis: Influence of glucosamine on interleukin-1beta-mediated effects in rat chondrocytes. Arthritis Rheum. 44:351–360. 2001. View Article : Google Scholar : PubMed/NCBI
20	Nakamura H, Shibakawa A, Tanaka M, Kato T and Nishioka K: Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol. 22:293–299. 2004.PubMed/NCBI
21	Derfoul A, Miyoshi AD, Freeman DE and Tuan RS: Glucosamine promotes chondrogenic phenotype in both chondrocytes and mesenchymal stem cells and inhibits MMP-13 expression and matrix degradation. Osteoarthritis Cartilage. 15:646–655. 2007. View Article : Google Scholar : PubMed/NCBI
22	Yoshimura M, Sakamoto K, Tsuruta A, Yamamoto T, Ishida K, Yamaguchi H and Nagaoka I: Evaluation of the effect of glucosamine administration on biomarkers for cartilage and bone metabolism in soccer players. Int J Mol Med. 24:487–494. 2009.PubMed/NCBI
23	Nagaoka I, Tsuruta A and Yoshimura M: Evaluation of cartilage and bone metabolism in collegiate athletes belonging to various sports clubs by analyzing type II collagen degradation and synthesis and type I collagen degradation. Juntendo Med J. 64 Suppl 1:122–127. 2018.
24	Garnero P, Piperno M, Gineyts E, Christgau S, Delmas PD and Vignon E: Cross sectional evaluation of biochemical markers of bone, cartilage, and synovial tissue metabolism in patients with knee osteoarthritis: Relations with disease activity and joint damage. Ann Rheum Dis. 60:619–626. 2001. View Article : Google Scholar : PubMed/NCBI
25	Radin EL and Rose RM: Role of subchondral bone in the initiation and progression of cartilage damage. Clin Orthop Relat Res. 1–40. 1986.
26	Bettica P, Cline G, Hart DJ, Meyer J and Spector TD: Evidence for increased bone resorption in patients with progressive knee osteoarthritis: Longitudinal results from the Chingford study. Arthritis Rheum. 46:3178–3184. 2002. View Article : Google Scholar : PubMed/NCBI
27	Nakamura H, Masuko K, Yudoh K, Kato T, Kamada T and Kawahara T: Effects of glucosamine administration on patients with rheumatoid arthritis. Rheumatol Int. 27:213–218. 2007. View Article : Google Scholar : PubMed/NCBI
28	Martirosyan DM and Singh J: A new definition of functional food by FFC: What makes a new definition unique? Functi Foods Health Dis. 5:209–223. 2015.